Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Registration Number
- NCT06512467
- Brief Summary
The investigators design a phase IIB clinical study to explore the efficacy and safety of Donafenib combined with Sintilimab and HAIC in neoadjuvant of resectable Hepatocellular Carcinoma.
- Detailed Description
This trial is a single-arm, non-randomized and single-center clinical study of Donafenib combined with Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular CarcinomaIt will estimate that 30 patients who met the study criteria will be enrolled in Tianjin Medical University Cancer Institute and Hospital and neoadjuvant in Donafenib combined with Sintilimab and HAIC. The investigators will follow up and collect subjects' data monthly to evaluate the efficacy and safety of treatment.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 30
-
Voluntarily join the study and sign the informed consent;
-
Age 18 ~ 80 years old (including 80 years old), male and female;
-
Patients with hepatohcellular carcinoma diagnosed clinically or confirmed by histology / cytology according to the code for diagnosis and treatment of primary liver cancer (2022 Edition);
-
Hepatocellular carcinoma and technically resectable (CNLC stage Ⅱb to Ⅲa), estimated residual liver volume >30%, in patients with cirrhosis, the residual liver volume is >40%. And meets at least one of the following conditions:
- The tumor is adjacent to large blood vessels or other organs, resulting in an expected surgical margin of less than 1cm;
- Cancer thrombus formation was associated with ipsilateral portal vein or hepatic vein, but the tumor thrombus did not accumulate in the main contralateral portal vein, contralateral portal vein, contralateral hepatic vein, and superior mesenteric vein;
-
At least one assessable lesion (mRECIST criteria),and did not receive radiotherapy or local treatmen;
-
ECOG 0 ~ 1;
-
Major organs are functioning normally. Hemoglobin ≥ 90 g / L; ANC ≥ 1.5 × 109/L； Platelet count ≥ 100 × 109/L； Albumin ≥ 28 g / L; Total bilirubin ≤ 3 × ULN; AST, ALT ≤ 5 × ULN； TSH ≤ ULN； INR or PT ≤ 1.5 × ULN, APTT ≤ ULN.
-
If HBsAg (+) and/or anti-HCV (+), antiviral therapy should be standard based on HBV DNA or HCV RNA test results;
-
Be able to cooperate to observe adverse events. -
- Cholangiocarcinoma, mixed cell carcinoma and fibrous laminar cell carcinoma are known
- Diffuse tumor lesions
- extrahepatic metastasis
- Active malignancies other than HCC occur within 5 years or at the same time, with the exception of cured skin basal cell carcinoma, cervical carcinoma in situ and thyroid form carcinoma;
- Received radical hepatectomy, systemic anticancer therapy for liver cancer (mainly including systemic chemotherapy, molecular targeted therapy, CTLA-4, PD-1/PD-L1 monoclonal antibody immunotherapy) and local liver therapy, including TACE, HAIC, TAE, local ablation, radiotherapy, etc;
- The following conditions were present during the course of the study: myocardial infarction, severe unstable angina pectoris, NYHA2 or higher cardiac insufficiency, poor arrhythmia control, symptomatic congestive heart failure, cerebrovascular accident;
- A history of hypertensive crisis or hypertensive encephalopathy;
- The subject has any history of active autoimmune disease or autoimmune disease (but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, pituitaritis, vasculitis, nephritis, hyperthyroidism, hypothyroidism; Subjects with vitiligo or childhood asthma are in complete remission and can be included as adults without any intervention; Asthma requiring medical intervention with bronchodilators will not be included);
- Subjects are receiving immunosuppressive, systemic or absorbable local hormone therapy for immunosuppressive purposes and continue to receive such therapy during the 2 weeks prior to enrollment;
- Abnormal coagulation (INR > 1.5 or APTT > 1.5 x ULN) with bleeding tendency or receiving thrombolysis or anticoagulation therapy;
- Known severe adverse reactions to Donafenib, sindillizumab, or severe allergic reactions to other monoclonal antibodies;
- The subject has a known history of psychotropic, alcohol, or drug abuse. -
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Donafenib combined with Sintilimab and HAIC HAIC Donafenib:200mg bid; Sintilimab:200mg Q3D; HAIC:Q3W. Donafenib combined with Sintilimab and HAIC Donafenib Donafenib:200mg bid; Sintilimab:200mg Q3D; HAIC:Q3W. Donafenib combined with Sintilimab and HAIC Sintilimab Donafenib:200mg bid; Sintilimab:200mg Q3D; HAIC:Q3W.
- Primary Outcome Measures
Name Time Method MPR(Major Pathological Response) 1 year After neoadjuvant therapy, the proportion of residual tumor cells was less than 30%.
- Secondary Outcome Measures
Name Time Method ORR(Objective Response Rate) 1 year The rate of participants that achieve either a complete response (CR) or a partial response (PR).
OS(Overall Survival) 3 year Overall survival is defined as time from the start of treatment until death due to any reason.
R0 resection： The tumor was completely resected, and the submicroscopic margin was negative, that is, no tumor remained.RFS(Recurrence-free Survival) 1 year The time experienced from the enrollment date until tumor recurrence or death from any cause, if the subject died before the disease recurred. Survival subjects whose tumor recurrence was not confirmed by the database deadline were deleted according to the date of the last imaging tumor assessment. The date of tumor recurrence was the date of the first imaging confirmation of tumor recurrence.
DCR(Disease Control Rate) 3 year The percentage of cases with remission (PR + CR) and stable lesions (SD) after treatment was assessable.
pCR(Pathological Complete Response) 1 year No residual tumor was found pathologically in patients with neoadjuvant therapy induced tumor regression.